Literature DB >> 9437201

Thrombin-induced thromboxane synthesis by human platelets. Properties of anion binding exosite I-independent receptor.

R A Henriksen1, G P Samokhin, P B Tracy.   

Abstract

These studies have examined the effects of thrombin-related agonists in stimulating thromboxane production by human platelets. The results presented show that (1) the maximal response elicited by thrombin receptor agonist peptide (TRAP) stimulation was 40% to 50% of that seen with thrombin or the thrombin mutant Thrombin Quick I; (2) pretreatment of platelets with prostaglandin E1 or genistein resulted in differential inhibition of thromboxane production in response to TRAP compared with either enzyme agonist; (3) an antibody to the thrombin receptor cleavage site that inhibits increases in intracellular [Ca2+] only partially reduced thromboxane production in response to 5 nmol+L thrombin and 15 nmol/L Thrombin Quick I; (4) preincubation with 20 mumol/L TRAP resulted in desensitization to further stimulation by 100 mumol/L TRAP, but not by 100 nmol/L thrombin; and (5) the response to thrombin after TRAP desensitization was completely inhibited by the tyrosine kinase inhibitor genistein and was independent of an intracellular [Ca2+] flux, The cumulative results may be explained by the existence of two proteolytically activated receptors that result in thromboxane production in response to thrombin. One is the thrombin receptor/substrate, PAR-1. Stimulation through the second receptor/substrate depends on a genistein-sensitive step, is independent of an intracellular Ca2+ flux, and is initiated by a thrombin-activated receptor that does not depend on interaction with anion-binding exosite I, as previously indicated by the relative activity of Thrombin Quick I in stimulating platelet aggregation and thromboxane production. The proposed second thrombin receptor on platelets represents an additional member of the class of proteolytically activated receptors.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9437201     DOI: 10.1161/01.atv.17.12.3519

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  6 in total

Review 1.  Thrombin and vascular inflammation.

Authors:  Milan Popović; Katarina Smiljanić; Branislava Dobutović; Tatiana Syrovets; Thomas Simmet; Esma R Isenović
Journal:  Mol Cell Biochem       Date:  2011-08-23       Impact factor: 3.396

Review 2.  Pregnancy-specific expression of protease-activated receptor 1: a therapeutic target for prevention and treatment of preeclampsia?

Authors:  Scott W Walsh; Jerome F Strauss
Journal:  Am J Obstet Gynecol       Date:  2022-02       Impact factor: 8.661

3.  Proteases Activate Pregnancy Neutrophils by a Protease-Activated Receptor 1 Pathway: Epigenetic Implications for Preeclampsia.

Authors:  Scott W Walsh; William H Nugent; Marwah Al Dulaimi; Sonya L Washington; Phoebe Dacha; Jerome F Strauss
Journal:  Reprod Sci       Date:  2020-06-15       Impact factor: 3.060

4.  Impaired activation of platelets lacking protein kinase C-theta isoform.

Authors:  Bela Nagy; Kamala Bhavaraju; Todd Getz; Yamini S Bynagari; Soochong Kim; Satya P Kunapuli
Journal:  Blood       Date:  2009-01-22       Impact factor: 22.113

Review 5.  Proteinase-activated receptors (PARs) - focus on receptor-receptor-interactions and their physiological and pathophysiological impact.

Authors:  Frank Gieseler; Hendrik Ungefroren; Utz Settmacher; Morley D Hollenberg; Roland Kaufmann
Journal:  Cell Commun Signal       Date:  2013-11-11       Impact factor: 5.712

Review 6.  The Road to Low-Dose Aspirin Therapy for the Prevention of Preeclampsia Began with the Placenta.

Authors:  Scott W Walsh; Jerome F Strauss
Journal:  Int J Mol Sci       Date:  2021-06-29       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.